Preparation method of deacetyl cefathiamidine
Through the reaction of N-bromoacetyl-D-7-ACA with N,N'-diisopropylthiourea, combined with high-performance liquid chromatography and activated carbon decolorization technology, a high-purity deacetylcephathiamidine was successfully prepared to solve the problem of The problems of impurities in cefothamidine are present, ensuring the safety and accuracy of the preparation.
Patent Information
- Application Number
- CN202210680073.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-06-16
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2042-06-16
AI Technical Summary
During the preparation of cefothiamidine, the mixed deacetyl 7-ACA in the 7-ACA raw material causes the presence of impurities, and cefothiamidine may degrade during storage to produce deacetyl cefothiamidine, which is difficult to uniquely synthesize through existing chemicals Route to obtain deacetylcephathamidine.
N-bromoacetyl-D-7-ACA is used as an intermediate, and reacted with N,N'-diisopropylthiourea, and reacted in the presence of alkali at 0°C to 40°C, and used high-performance liquid chromatography The high-purity N-bromoacetyl-D-7-ACA was separated, followed by reaction with N,N'-diisopropylthiourea, and the temperature was controlled at 30°C to 40°C, and finally obtained by decolorizing activated carbon and crystallization solvent. Purified deacetylcephathamidine.
The efficient preparation of deacetylcephathiamidine is achieved, with a purity of more than 99.0%. It can be used as a standard reference product to accurately measure the content of impurities in cephathiamidine to ensure the safety of medication.
Smart Images

Figure BDA0003698003170000011 
Figure BDA0003698003170000021 
Figure BDA0003698003170000041
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of pharmaceuticals and relates to a preparation method of deacetyl cefathiamidine. Background Art
[0002] Cefathiamidine, also known as cephalosporin 18, is the first generation of cephalosporin antibacterial agent developed by my country. It exerts its antibacterial effect by inhibiting the synthesis of bacterial cell walls. It has a strong effect on Staphylococcus aureus, Streptococcus viridans, and Pneumococcus. It has unique antibacterial activity against enterococci. It is mainly used for respiratory system, hepatobiliary system, five sense organs, and urinary tract caused by sensitive bacteria. Its chemical name is: (6R,7R)-3-[(acetyloxy)methyl]-7-[α-(N,N-diisopropyl amidine thio)acetylamino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid betaine, and its chemical formula is C 19 H 28 N4O6S2.
[0003] At present, 7-ACA is commonly used as a raw material for the production of cefathiamidine, which reacts with bromoacetyl bromide to generate N-bromoacetyl-7-ACA, which then reacts with N,N'-diisopropylthiourea to generate a crude cefathiamidine product. The crude product is further refined to obtain cefathiamidine that meets the requirements of the pharmacopoeia. The production process reaction formula is as follows:
[0004]
[0005] In the preparation of cefathiamidine, the 7-ACA raw material is mixed with deacetyl 7-ACA (hereinafter referred to as D-7-ACA), so deacetyl cefathiamidine is an impurity that may exist in cefathiamidine. In addition, cefathiamidine may also degrade to produce deacetyl cefathiamidine during storage. Therefore, it is necessary to synthesize the deacetyl cefathiamidine as a standard reference substance to accurately measure the content of the impurity in cefathiamidine.
[0006] People have also considered synthesizing deacetyl cefuroxime using the same chemical synthesis route as cefuroxime, that is, using deacetyl 7-ACA as a raw material to synthesize deacetyl cefuroxime. However, from the structural formula of D-7-ACA, it can be seen that D-7-ACA has -OH at the 3rd position and -NH2 at the 7th position, that is, there are multiple reaction sites. In the reaction of D-7-ACA with bromoacetyl bromide, the following products will be produced:
[0007]
[0008] That is, bromoacetyl bromide reacts with -OH at position 3 or -NH2 at position 7 of D-7-ACA, or reacts with them simultaneously, and therefore, N-bromoacetyl-D-7-ACA cannot be obtained exclusively. Summary of the invention
[0009] Sinopharm Weiqida Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise controlled by China National Pharmaceutical Group Corporation. It is one of the Sinopharm Datong Antibiotic Industrial Bases. Its main products are cephalosporins, penicillin pharmaceutical intermediates, APIs, powder injections and clavulanic acid pharmaceutical APIs. It is a leading domestic enterprise in the production and development of cephalosporins and penicillins. In response to the above problems, the R&D personnel explored and isolated N-bromoacetyl-D-7-ACA, and then N-bromoacetyl-D-7-ACA reacted with N,N'-diisopropylthiourea to obtain deacetyl cefathiamidine.
[0010] Therefore, the object of the present invention is to provide a method for preparing deacetyl cefathiamidine.
[0011] According to the present invention, the preparation method of deacetyl cefathiamidine provided by the present invention comprises:
[0012] (1) Preparation of N-bromoacetyl-D-7-ACA
[0013] At 0°C to 40°C, in the presence of a base, D-7-ACA is dissolved in water, and then a first organic solvent is added, and bromoacetyl bromide is added dropwise, and the reaction is stirred for 1 to 4 hours; after the reaction is completed, the aqueous phase is separated by standing and layering or the organic solvent is removed by reduced pressure distillation to obtain an aqueous phase; at room temperature, the pH of the aqueous phase is adjusted to 0.5 to 2.5 with an acid, and solid crystals are precipitated, and a solid is obtained by filtration;
[0014] The solid was dissolved in a second organic solvent, and N-bromoacetyl-D-7-ACA was separated by preparative high performance liquid chromatography, wherein the preparative high performance liquid chromatography was as follows:
[0015] Chromatographic column: C18 packing column;
[0016] Eluent: mixture of water and acetonitrile;
[0017] Collect the eluted fraction with a retention time of 10-11 min, and combine the eluent of the fraction with a purity of ≥98% and concentrate it, solid crystals precipitate, filter, wash with water, and dry to obtain N-bromoacetyl-D-7-ACA solid;
[0018] (2) Preparation of deacetyl cefathiamidine
[0019] At 0°C to 40°C, in the presence of a base, dissolving N-bromoacetyl-D-7-ACA in a third organic solvent, and then adding N,N'-diisopropylthiourea; controlling the reaction temperature at 30°C to 40°C, stirring the reaction for 1 to 4 hours; after the reaction is completed, cooling to 0°C to 10°C, solid crystals precipitate, and filtering to obtain a crude deacetyl cefathiamidine product;
[0020] (3) Purification of deacetyl cefathiamidine
[0021] The crude deacetyl cefathiamidine obtained above is dissolved in a fourth solvent at 0°C to 20°C, and then decolorized with activated carbon. After filtering, a crystallization solvent is added to the filtrate to crystallize the deacetyl cefathiamidine. After filtering, washing and drying, purified deacetyl cefathiamidine is obtained.
[0022] The preparation method of deacetylcefothiamidine of the present invention is described in more detail below.
[0023] In the preparation of N-bromoacetyl-D-7-ACA in step (1), D-7-ACA is dissolved in water at 0°C to 40°C, preferably 0°C to 5°C, in the presence of a base, wherein D-7-ACA is selected from one or two of diethylamine, triethylamine, N,N-diisopropylethylamine, potassium carbonate, sodium carbonate and sodium bicarbonate, and preferably triethylamine and / or sodium bicarbonate. Then, a first organic solvent is added thereto, wherein the first organic solvent is selected from one or two of toluene, dichloromethane, acetone, tetrahydrofuran and N,N-dimethylformamide, and preferably toluene or acetone; the ratio of the first organic solvent to water is 0.4 to 2.5:1, by volume.
[0024] Bromoacetyl bromide is added dropwise, and the molar ratio of D-7-ACA to bromoacetyl bromide is 1:1 to 3, and preferably 1:1.2 to 3.0. Under stirring, D-7-ACA and bromoacetyl bromide react for 1 to 4 hours. D-7-ACA has -OH at position 3 and -NH2 at position 7, that is, there are multiple reaction sites. In the reaction of D-7-ACA and bromoacetyl bromide, the following three products are produced:
[0025]
[0026] Therefore, it is necessary to separate N-bromoacetyl-D-7-ACA from the reaction product. After the reaction of D-7-ACA and bromoacetyl bromide is completed, the aqueous phase is separated by standing and layering, or the organic solvent is removed by reduced pressure distillation to obtain an aqueous phase. At room temperature, the pH of the aqueous phase is adjusted to 0.5-2.5, preferably 1.0-2.0, with an acid, and a solid crystal is precipitated, and a solid is obtained by filtration, wherein the acid can be hydrochloric acid, such as 6M hydrochloric acid.
[0027] The solid is dissolved in a second organic solvent, the second organic solvent is one or both selected from N,N-dimethylformamide and dimethyl sulfoxide, preferably N,N-dimethylformamide. High-purity N-bromoacetyl-D-7-ACA is separated by preparative high performance liquid chromatography, wherein the preparative high performance liquid chromatography conditions are as follows:
[0028] Chromatographic column: C18 packing column;
[0029] Eluent: a mixture of water and acetonitrile.
[0030] More specifically,
[0031] Chromatographic column: C18 packing column (10μm, 50mm*250mm);
[0032] Eluent: water: acetonitrile = 87:13 (V / V);
[0033] Detection wavelength: UV254nm;
[0034] Flow rate: 16-21L / min;
[0035] The eluted fractions with a retention time of 10-11 min were collected, and the eluents of the fractions with a purity of ≥98% were combined and concentrated. Solid crystals were precipitated, filtered, washed with water, and dried to obtain high-purity N-bromoacetyl-D-7-ACA solid.
[0036] In the process of separating N-bromoacetyl-D-7-ACA by preparative high performance liquid chromatography, the inventors found that byproducts 1 and 2 were difficult to separate due to their similar structures to N-bromoacetyl-D-7-ACA. After repeated experiments, the above chromatographic conditions were screened out, and the eluent of N-bromoacetyl-D-7-ACA with a purity of ≥98% was successfully separated.
[0037] For example, when selecting an eluent, when a mixture of methanol and water is used as the mobile phase, the liquid chromatogram is as follows: Figure 1 As shown, it can be seen that the peaks are irregular and the separation is poor, and it is impossible to separate N-bromoacetyl-D-7-ACA from byproducts 1 and 2. When a mixture of acetonitrile and water is used as the mobile phase, at a flow rate of 35 L / min, the liquid chromatogram is as follows Figure 2 As shown, it can be seen that the separation degree is only 0.2; however, when the flow rate is adjusted to a relatively low flow rate of 16-21L / min, the liquid chromatogram is as follows Figure 3 As shown, it can be seen that a good separation effect was achieved.
[0038] In the preparation of deacetyl cefathiamidine in step (2), N-bromoacetyl-D-7-ACA is dissolved in a third organic solvent at 0°C to 40°C, preferably 0°C to 5°C, in the presence of a base, wherein the base is one or two selected from diethylamine, triethylamine and N,N-diisopropylethylamine, and preferably triethylamine; and the third organic solvent is one or two selected from dichloromethane, chloroform, toluene, methanol, ethanol and isopropanol, and preferably dichloromethane.
[0039] In the third organic solvent, in the presence of a base, N-bromoacetyl-D-7-ACA is dissolved, and then N,N'-diisopropylthiourea is added. The reaction temperature is controlled at 30°C to 40°C, preferably 35°C to 40°C, and the reaction is stirred for 1 to 4 hours; after the reaction is completed, the temperature is lowered to 0°C to 10°C, preferably 0°C to 5°C, solid crystals are precipitated, and the crude deacetyl cefathiamidine is obtained by filtration. The molar ratio of N-bromoacetyl-D-7-ACA to N,N'-diisopropylthiourea is 1:1 to 3, and preferably 1:1 to 2.
[0040] In the purification of deacetyl cefathiamidine in step (3), the crude deacetyl cefathiamidine obtained above is dissolved in a fourth solvent at 0°C to 20°C, preferably 0°C to 5°C, and then decolorized with activated carbon. After filtering, a crystallization solvent is added to the filtrate to crystallize deacetyl cefathiamidine, and the deacetyl cefathiamidine is filtered, washed and dried to obtain purified deacetyl cefathiamidine.
[0041] Wherein, the fourth solvent is one or two selected from water, N,N-dimethylformamide, methanol, ethanol and isopropanol, and is preferably a water-ethanol mixed solvent; the crystallization solvent is one or two selected from acetone, dichloromethane and ethyl acetate, and is preferably acetone.
[0042] The deacetylcefotaxime obtained by the above preparation method has a purity of more than 99.0%, and can be used as a standard reference substance to accurately measure the content of deacetylcefotaxime impurities in cefathiamidine raw materials and preparations to ensure the safety of medication. BRIEF DESCRIPTION OF THE DRAWINGS
[0043] Figure 1 It is a preparative high performance liquid chromatogram of the reaction product of D-7-ACA and bromoacetyl bromide, wherein a mixture of methanol and water is used as the mobile phase;
[0044] Figure 2 The figure is a preparative high performance liquid chromatogram of the reaction product of D-7-ACA and bromoacetyl bromide, wherein a mixture of acetonitrile and water is used as the mobile phase at a flow rate of 35 L / min;
[0045] Figure 3 The figure is a preparative high performance liquid chromatogram of the reaction product of D-7-ACA and bromoacetyl bromide, wherein a mixture of acetonitrile and water is used as the mobile phase at a flow rate of 16-21 L / min;
[0046] Figure 4 This is the hydrogen nuclear magnetic resonance spectrum of N-bromoacetyl-D-7-ACA prepared in Example 1 of the present invention;
[0047] Figure 5 The carbon NMR spectrum of N-bromoacetyl-D-7-ACA prepared in Example 1 of the present invention;
[0048] Figure 6 The hydrogen nuclear magnetic resonance spectrum of deacetyl cefathiamidine prepared in Example 1 of the present invention;
[0049] Figure 7 This is the carbon NMR spectrum of deacetyl cefathiamidine prepared in Example 1 of the present invention. DETAILED DESCRIPTION
[0050] The preparation method of deacetyl cefathiamidine of the present invention is further described in detail below by way of examples, and the protection scope of the present invention is not limited to the following examples, which are listed only for illustrative purposes and are not intended to limit the present invention in any way.
[0051] Example 1
[0052] (1) Preparation of N-bromoacetyl-D-7-ACA
[0053] Add 375 mL of water to the reaction flask, cool to 3°C, add 15 g (0.0651 mol) of D-7-ACA under stirring, begin to add 16.4 g (0.1621 mol) of triethylamine dropwise to dissolve D-7-ACA, and then add 170 mL of toluene; add 16.6 g (0.0822 mol) of bromoacetyl bromide dropwise, and react at 0°C to 5°C with stirring for 4 hours; then turn off stirring, let stand to separate the layers, separate the aqueous layer, add 6 M hydrochloric acid dropwise at room temperature, adjust the pH of the feed solution to 1.0, and solid crystals will precipitate. After filtration and washing with water, a solid wet material (34 g) is obtained.
[0054] 34 g of the solid wet material was dissolved in 60 mL of DMF to separate N-bromoacetyl-D-7-ACA by preparative high performance liquid chromatography. The equipment used was a DAC-50 preparative liquid chromatography instrument. The chromatographic conditions were as follows:
[0055] Chromatographic column: C18 packing column (10μm, 50mm*250mm);
[0056] Eluent: water: acetonitrile = 87:13 (V / V);
[0057] Detection wavelength: UV254nm;
[0058] Isocratic elution flow rate: 18 L / min;
[0059] Sample volume: 20-25mL / time.
[0060] The eluted fraction with a retention time of 10-11 min was collected, and the eluent of the fraction with a purity of ≥98% was combined, and the acetonitrile and part of DMF were removed by vacuum concentration. Solids were precipitated during the concentration process, and the crystals were stirred for 30 min, filtered, and the filter cake was slurried and washed 3-5 times with 400 mL of water. The wet material was taken out and placed in a vacuum drying oven for drying to obtain 10.7 g of the intermediate N-bromoacetyl-D-7-ACA finished product with a yield of 47% and a purity of 98.4%.
[0061] Figure 4 and Figure 5 They are the hydrogen spectrum and carbon spectrum of NMR of N-bromoacetyl-D-7-ACA respectively.
[0062] (2) Preparation of deacetyl cefathiamidine
[0063] Add 100 mL of dichloromethane and 10 g (0.0285 mol) of N-bromoacetyl-D-7-ACA to a dry reaction bottle, cool to 3 ° C, and drop 3.2 g (0.0316 mol) of triethylamine until the system is dissolved; then add 6.9 g (0.0430 mol) of N, N'-diisopropylthiourea, heat to 40 ° C, and keep warm for 4 hours; after the reaction is completed, cool to 1 ° C for crystallization; filter, and wash the filter cake with 40 mL of dichloromethane for 3 times to obtain 9.5 g of crude deacetyl cefathiamidine wet material.
[0064] (3) Purification of deacetyl cefathiamidine
[0065] The above 9.5 g crude deacetyl cefathiamidine was dissolved in a mixed solution of 50 mL ethanol-water (95%-5%), the temperature was controlled at 3° C., 2 g activated carbon was added, and the mixture was stirred for decolorization for 30 min. After decolorization, the mixture was filtered, and the activated carbon was rinsed with 10 mL water. The obtained filtrate was combined; 300 mL acetone was added to the filtrate, crystals were precipitated, filtered, and washed to obtain a deacetyl cefathiamidine wet material, which was placed in a vacuum drying oven and vacuumed for 0.5 hours, and then vacuum dried at 26-28° C. to obtain 4.5 g deacetyl cefathiamidine with a yield of 36% and a purity of 99.3%.
[0066] Figure 6 and Figure 7 They are the hydrogen spectrum and carbon spectrum of deacetylcefotaxime nuclear magnetic resonance, respectively.
[0067] Example 2
[0068] (1) Preparation of N-bromoacetyl-D-7-ACA
[0069] To the reaction flask, add 100 mL of water, cool to 1°C, add 15 g (0.0651 mol) of D-7-ACA under stirring, begin to dropwise add 300 g of sodium bicarbonate solution (containing 16 g (0.1905 mol) of sodium bicarbonate) to dissolve D-7-ACA, and then add 230 mL of acetone; dropwise add 20 g (0.099 mol) of bromoacetyl bromide, and stir the reaction at 0°C to 5°C for 3 hours; then concentrate under reduced pressure to evaporate the acetone, add 8 M hydrochloric acid dropwise at room temperature, adjust the pH of the feed solution to 1.3, and solid crystals precipitate. After filtration and washing with water, a solid wet material (29 g) is obtained.
[0070] 29 g of the above solid wet material was dissolved in 60 mL of DMF to separate N-bromoacetyl-D-7-ACA by preparative high performance liquid chromatography. The equipment used was a DAC-50 preparative liquid chromatography instrument. The chromatogram was as follows:
[0071] Chromatographic column: C18 packing column (10μm, 50mm*250mm);
[0072] Eluent: water: acetonitrile = 87:13 (V / V);
[0073] Detection wavelength: UV254nm;
[0074] Isocratic elution flow rate: 20L / min;
[0075] Sample volume: 20-25mL / time.
[0076] The eluted fraction with a retention time of 10-11 min was collected, and the eluent of the fraction with a purity of ≥98% was combined, and the acetonitrile and part of DMF were removed by vacuum concentration. Solids were precipitated during the concentration process, and the crystals were stirred for 30 min, filtered, and the filter cake was slurried and washed 3-5 times with 400 mL of water. The wet material was taken out and placed in a vacuum drying oven for drying to obtain 8 g of the intermediate N-bromoacetyl-D-7-ACA finished product with a yield of 35% and a purity of 98.7%.
[0077] (2) Preparation of deacetyl cefathiamidine
[0078] Add 60 mL of dichloromethane, 10 mL of methanol and 8 g (0.0227 mol) of N-bromoacetyl-D-7-ACA to a dry reaction bottle, cool to 5 ° C, and add 2.4 g (0.0239 mol) of triethylamine dropwise until the system is dissolved; then add 7.3 g (0.0455 mol) of N, N'-diisopropylthiourea, heat to 38 ° C, and keep warm for 4 hours; after the reaction is completed, cool to 5 ° C for crystallization; filter, and wash the filter cake with 40 mL of dichloromethane for 3 times to obtain 7.6 g of crude deacetyl cefuroxime wet material.
[0079] (3) Purification of deacetyl cefathiamidine
[0080] The above 7.6 g of crude deacetyl cefathiamidine was dissolved in a mixed solution of 50 mL of ethanol-N,N-dimethylformamide (93%-7%), the temperature was controlled at 0°C to 5°C, 2 g of activated carbon was added, and the mixture was stirred for decolorization for 30 min. After decolorization, the mixture was filtered, and the activated carbon was rinsed with a mixed solution of 10 mL of ethanol-N,N-dimethylformamide (93%-7%). The obtained filtrate was combined; 400 mL of acetone was added to the filtrate to precipitate crystals, which were filtered and washed to obtain a wet deacetyl cefathiamidine material. The wet material was placed in a vacuum drying oven and vacuumed for 0.5 hours, and then vacuum dried at 26-28°C to obtain 3.2 g of deacetyl cefathiamidine with a yield of 32% and a purity of 99.2%.
Claims
1. A method for preparing deacetyl cefathiamidine, comprising: (1) Preparation of N-bromoacetyl-D-7-ACA At 0°C to 40°C, in the presence of a base, D-7-ACA is dissolved in water, and then a first organic solvent is added, and bromoacetyl bromide is added dropwise, and the reaction is stirred for 1 to 4 hours; after the reaction is completed, the aqueous phase is separated by standing and layering or the organic solvent is removed by reduced pressure distillation to obtain an aqueous phase; at room temperature, the pH of the aqueous phase is adjusted to 0.5 to 2.5 with an acid, and solid crystals are precipitated, and a solid is obtained by filtration; The solid was dissolved in a second organic solvent, and N-bromoacetyl-D-7-ACA was separated by preparative high performance liquid chromatography, wherein the preparative high performance liquid chromatography conditions are as follows: Chromatographic column: C18 packing column; Eluent: a mixture of water and acetonitrile in a volume ratio of 87:13; Flow rate: 16-21L / min; Collect the eluted fraction with a retention time of 10-11 min, and combine the eluent of the fraction with a purity of ≥98% and concentrate it, solid crystals precipitate, filter, wash with water, and dry to obtain N-bromoacetyl-D-7-ACA solid; Wherein, the first organic solvent is one or two selected from toluene, dichloromethane, acetone and tetrahydrofuran, and the second organic solvent is one or two selected from N,N-dimethylformamide and dimethyl sulfoxide; (2) Preparation of deacetyl cefathiamidine At 0°C to 40°C, in the presence of a base, dissolving N-bromoacetyl-D-7-ACA in a third organic solvent, and then adding N,N'-diisopropylthiourea; controlling the reaction temperature at 30°C to 40°C, stirring the reaction for 1 to 4 hours; after the reaction is completed, cooling to 0°C to 10°C, solid crystals precipitate, and filtering to obtain a crude deacetyl cefathiamidine product; wherein the third organic solvent is one or two selected from dichloromethane, chloroform, toluene, methanol, ethanol and isopropanol; (3) Purification of deacetyl cefathiamidine At 0°C to 20°C, the crude deacetyl cefathiamidine obtained above is dissolved in a fourth solvent, and then decolorized with activated carbon. After filtering, a crystallization solvent is added to the filtrate to crystallize the deacetyl cefathiamidine. After filtering, washing and drying, purified deacetyl cefathiamidine is obtained, wherein the fourth solvent is one or two selected from water, N,N-dimethylformamide, methanol, ethanol and isopropanol, and the crystallization solvent is one or two selected from acetone, dichloromethane and ethyl acetate.
2. The method for preparing deacetyl cefathiamidine according to claim 1, characterized in that In the preparation of N-bromoacetyl-D-7-ACA in step (1), the preparative HPLC conditions are as follows: Chromatographic column: C18 packing column, 10μm, 50mm*250mm; Eluent: a mixture of water and acetonitrile in a volume ratio of 87:13; Detection wavelength: UV254nm; Flow rate: 16-21L / min.
3. The method for preparing deacetyl cefathiamidine according to claim 1, characterized in that In the preparation of N-bromoacetyl-D-7-ACA in step (1), the base is one or two selected from diethylamine, triethylamine, N,N-diisopropylethylamine, potassium carbonate, sodium carbonate and sodium bicarbonate.
4. The method for preparing deacetyl cefathiamidine according to claim 1, characterized in that In the preparation of N-bromoacetyl-D-7-ACA in step (1), the first organic solvent is toluene or acetone; the ratio of the first organic solvent to water is 0.4 to 2.5:1, by volume; and the base is triethylamine and / or sodium bicarbonate.
5. The method for preparing deacetyl cefathiamidine according to claim 1, characterized in that In the preparation of N-bromoacetyl-D-7-ACA in step (1), the molar ratio of D-7-ACA to bromoacetyl bromide is 1:1-3.
6. The method for preparing deacetyl cefathiamidine according to claim 1, characterized in that In the preparation of N-bromoacetyl-D-7-ACA in step (1), the pH of the aqueous phase is adjusted to 1.0-2.0 with hydrochloric acid at room temperature, solid crystals are precipitated, and a solid is obtained by filtration.
7. The method for preparing deacetyl cefathiamidine according to claim 1, characterized in that In the preparation of deacetyl cefathiamidine in step (2), the base is one or two selected from diethylamine, triethylamine and N,N-diisopropylethylamine, and the third organic solvent is dichloromethane.
8. The method for preparing deacetyl cefathiamidine according to claim 1, characterized in that In the preparation of deacetyl cefathiamidine in step (2), the molar ratio of N-bromoacetyl-D-7-ACA to N,N'-diisopropylthiourea is 1:1-3.
9. The method for preparing deacetyl cefathiamidine according to claim 1, characterized in that In the step (3) of refining deacetyl cefathiamidine, the fourth solvent is a water-ethanol mixed solvent; and the crystallization solvent is acetone.
Citation Information
Patent Citations
Cefathiamidine compound and new preparation method thereof
CN102010428A
(6R,7R)-3-methyl-7-[alpha-(N,N'-diisopropyl amidine thio)-acetylamino]-8-oxo-5-thia-1-azabicyclo[4,2,0]-oct-2-alkene-2-formic betaine crystals
CN102838621A
(6R, 7R)-3-hydroxymethyl-7-[alpha-(N, N'-diisopropylamidino thio)-acetamido]-8-oxo-5-thia-1-azabicycle [4, 2, 0]-oct-2-ene-2-carboxylic acid
CN102863461A
Method of preparing desacetyl cefathiamidine
CN104450851A
Cefathiamidine compound and preparation thereof and preparation methods of cefathiamidine compound and preparation
CN106220647A
